Pfiz­er leads top-sell­ing phar­ma fore­cast — Eval­u­ate re­port

Pfiz­er upped its 2022 Covid vac­cine guid­ance by $2 bil­lion last quar­ter on the heels of its bi­va­lent boost­er launch. While we’ve yet to see the full-year fig­ures, Eval­u­ate ex­pects the good for­tune will con­tin­ue in­to this year.

The phar­ma gi­ant made the top of Eval­u­ate’s pro­ject­ed list of top-sell­ing phar­ma com­pa­nies in 2023, with a fore­cast of more than $70 bil­lion in pre­scrip­tion drug sales. The com­pa­ny made a record $81 bil­lion in 2021, and $22.6 bil­lion in Q3 of last year alone. De­spite slow boost­er up­take in the US — just over 15% of Amer­i­cans 5 years and old­er have rolled up their sleeves — Eval­u­ate pre­dicts that Comir­naty and Paxlovid sales will make Pfiz­er a top earn­er next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER